Today, Atomo Diagnostics and partner Mylan have jointly announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO PQ). The WHO PQ process includes a rigorous evaluation of the test’s...
Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford is a major healthcare company and device manufacturer that commercialises pioneering medical products in its own brand to enhance access to diagnostics, encourage...
Sydney, Australia and Woodstock, England – 05 June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford acquires exclusive rights to Atomo’s HIV rapid tests for commercialisation under...
Atomo Diagnostics' CEO, John Kelly, today announced that the Atomo HIV Self Test has been approved by the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D); a special process determined by Unitaid and The Global Fund to expedite access to innovative diagnostic products in advance...
Sydney, Australia, 7 December 2017 | Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources. Atomo HIV Self...
Sydney, Australia, May 30, 2017| Multi-award winning medical device innovator Atomo Diagnostics today announced its pioneering HIV self test product has been approved for sale in Kenya. Following successful product evaluations and in-field studies conducted in Kenya by investigators from the Kenya Medical Research Institute (KEMRI), Nairobi, Atomo...